source
- Legend surges on early data for ‘in vivo’ lymphoma cell therapyInitial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.
- FDA releases draft guidance to speed cell and gene therapy approvalsThe FDA announced a draft guidance aimed at helping developers bring gene therapies to patients more quickly. It encourages use of publicly available scientific data and existing platform knowledge…